Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog


Shutterstock photo

Roche ( RHHBY ) announced that its cobas 6800/8800 systems - two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.

Both the systems are designed for donor screening, viral load monitoring, women's health and microbiology testing. The systems enable labs to generate a high volume of results faster with fewer manual steps, thereby improving laboratory operations. In addition, the systems ensure a safe blood supply through better screening.

The portfolio launched also includes the cobas p680 instrument to support the creation of donor sample pools along with three next-generation assays for donor screening - cobas MPX, cobas WNV and cobas HEV. Roche plans to release a next-generation cobas DPX test by the fourth quarter to complete the donor screening menu.

We note that the systems are not currently available in the U.S.

Apart from providing therapeutic products and services for diverse medical needs, Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases.

Roche has a broad portfolio of diagnostic tests with more than a hundred high-quality Elecsys assays for immune testing along with a new generation of fully automated cobas analyzers for improved medical decision making, scheduling and efficiency.

We are impressed by Roche's efforts to strengthen its Diagnostic division.

Roche was in the news recently when it announced that it has entered into a definitive merger agreement to acquire California-based biotechnology company InterMune, Inc. ( ITMN ) for $74.00 per share or $8.3 billion.

Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader healthcare sector include Allergan ( AGN ) and Gilead Sciences ( GILD ). Both sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

INTERMUNE INC (ITMN): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: RHHBY , ITMN , AGN , GILD

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by